Biomarkers of Vitamin D Status and Risk of ESRD

American Journal of Kidney Diseases

Volumn 67, Issue 2, 2016, Pages 235-242

  Rebholz, Casey M ^a   Grams, Morgan E ^a,b   Lutsey, Pamela L ^c   Hoofnagle, Andrew N ^d   Misialek, Jeffrey R ^c   Inker, Lesley A ^e   Levey, Andrew S ^e   Selvin, Elizabeth ^a,b   Hsu, Chi Yuan ^f   Kimmel, Paul L ^g   Vasan, Ramachandran S ^h   Eckfeldt, John H ⁱ   Coresh, Josef ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Biological markers; chronic renal failure; end stage renal disease (ESRD); mineral metabolism biomarker; risk factors; Vitamin D; Vitamin D insufficiency; Vitamin D binding protein

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; PARATHYROID HORMONE; PHOSPHATE; VITAMIN D; VITAMIN D BINDING PROTEIN; 1,25-DIHYDROXYVITAMIN D; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER;

ADULT; ALBUMINURIA; ARTICLE; BLACK PERSON; CALCIUM BLOOD LEVEL; CASE CONTROL STUDY; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; GENOTYPE; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINERAL METABOLISM; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PROSPECTIVE STUDY; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; VITAMIN BLOOD LEVEL; AGED; ANALOGS AND DERIVATIVES; BLOOD; DEMOGRAPHY; FOLLOW UP; KIDNEY FAILURE, CHRONIC; RISK FACTOR;

AGED; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RESIDENCE CHARACTERISTICS; RISK FACTORS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84951139498     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2015.08.026     Document Type: Article

References (40)

1. L. Craver, M.P. Marco, I. Martinez, and et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 - achievement of K/DOQI target ranges Nephrol Dial Transplant 22 4 2007 1171 1176
2. J.J. Scialla, B.C. Astor, T. Isakova, H. Xie, L.J. Appel, and M. Wolf Mineral metabolites and CKD progression in African Americans J Am Soc Nephrol 24 1 2013 125 135
3. A. Levin, G.L. Bakris, M. Molitch, and et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease Kidney Int 71 1 2007 31 38
4. C.R. Doorenbos, J. van den Born, G. Navis, and M.H. de Borst Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism Nat Rev Nephrol 5 12 2009 691 700
5. M. Koizumi, H. Komaba, and M. Fukagawa Parathyroid function in chronic kidney disease: role of FGF23-klotho axis Contrib Nephrol 180 2013 110 123
6. W. Reinhardt, S. Dolff, P. John, A. Kribben, and O. Witzke Impact of renal failure on metabolic bone parameters in a vitamin D-deficient patient cohort Clin Nephrol 75 5 2011 403 409
7. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 60 5 2012 850 886
8. P. Kandula, M. Dobre, J.D. Schold, M.J. Schreiber Jr., R. Mehrotra, and S.D. Navaneethan Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials Clin J Am Soc Nephrol 6 1 2011 50 62
9. P. Ravani, F. Malberti, G. Tripepi, and et al. Vitamin D levels and patient outcome in chronic kidney disease Kidney Int 75 1 2009 88 95
10. M.L. Melamed, B. Astor, E.D. Michos, T.H. Hostetter, N.R. Powe, and P. Muntner 25-Hydroxyvitamin D levels, race, and the progression of kidney disease J Am Soc Nephrol 20 12 2009 2631 2639
11. D.D. Bikle, P.K. Siiteri, E. Ryzen, and J.G. Haddad Serum protein binding of 1,25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels J Clin Endocrinol Metab 61 5 1985 969 975
12. C.M. Mendel The free hormone hypothesis: a physiologically based mathematical model Endocr Rev 10 3 1989 232 274
13. I. Bhan, C.E. Powe, A.H. Berg, and et al. Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients Kidney Int 82 1 2012 84 89
14. D.D. Bikle, E. Gee, B. Halloran, M.A. Kowalski, E. Ryzen, and J.G. Haddad Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein J Clin Endocrinol Metab 63 4 1986 954 959
15. J. Arnaud, and J. Constans Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP) Hum Genet 92 2 1993 183 188
16. C.E. Powe, M.K. Evans, J. Wenger, and et al. Vitamin D-binding protein and vitamin D status of black Americans and white Americans N Engl J Med 369 21 2013 1991 2000
17. 3 C-3 epimer: distribution, correlates, and reclassification of 25-hydroxyvitamin D status in the population-based Atherosclerosis Risk in Communities Study (ARIC) Clin Chim Acta 442 2015 75 81
18. The ARIC Investigators The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives Am J Epidemiol 129 4 1989 687 702
19. L.D. Bash, J. Coresh, A. Kottgen, and et al. Defining incident chronic kidney disease in the research setting: the ARIC Study Am J Epidemiol 170 4 2009 414 424
20. A.S. Levey, L.A. Stevens, C.H. Schmid, and et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 9 2009 604 612
21. T.J. Laha, F.G. Strathmann, Z. Wang, I.H. de Boer, K.E. Thummel, and A.N. Hoofnagle Characterizing antibody cross-reactivity for immunoaffinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry Clin Chem 58 12 2012 1711 1716
22. K. Musunuru, G. Lettre, T. Young, and et al. Candidate gene association resource (CARe): design, methods, and proof of concept Circ Cardiovasc Genet 3 3 2010 267 275
23. A. Vermeulen, L. Verdonck, and J.M. Kaufman A critical evaluation of simple methods for the estimation of free testosterone in serum J Clin Endocrinol Metab 84 10 1999 3666 3672
24. A. Braun, R. Bichlmaier, and H. Cleve Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types Hum Genet 89 4 1992 401 406
25. F.F. Safadi, P. Thornton, H. Magiera, and et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein J Clin Invest 103 2 1999 239 251
26. D.D. Bikle, and E. Gee Free, and not total, 1,25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes Endocrinology 124 2 1989 649 654
27. M.F. Holick, N.C. Binkley, H.A. Bischoff-Ferrari, and et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline J Clin Endocrinol Metab 96 7 2011 1911 1930
28. W. Al-Badr, and K.J. Martin Vitamin D and kidney disease Clin J Am Soc Nephrol 3 5 2008 1555 1560
29. M.F. Holick Vitamin D deficiency N Engl J Med 357 3 2007 266 281
30. J.R. Dominguez, M.G. Shlipak, M.A. Whooley, and J.H. Ix Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes J Am Soc Nephrol 24 4 2013 647 654
31. S. Nakanishi, J.J. Kazama, T. Nii-Kono, and et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients Kidney Int 67 3 2005 1171 1178
32. T. Shimada, H. Hasegawa, Y. Yamazaki, and et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis J Bone Miner Res 19 3 2004 429 435
33. A.K. Uzum, S. Salman, A. Telci, and et al. Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term Eur J Endocrinol 163 5 2010 825 831
34. 2) on circulating 1,25(OH)2-vitamin D and fibroblast growth factor-23 (FGF-23) in vitamin D insufficiency J Clin Endocrinol Metab 98 2 2013 550 556
35. C.M. Rebholz, M.E. Grams, J. Coresh, and et al. Serum fibroblast growth factor-23 is associated with incident kidney disease J Am Soc Nephrol 26 1 2015 192 200
36. A.Y. Adema, M.H. de Borst, P.M. Ter Wee, M.G. Vervloet NIGRAM Consortium Dietary and pharmacological modification of fibroblast growth factor-23 in chronic kidney disease J Ren Nutr 24 3 2014 143 150
37. M.W. Taal, V. Thurston, N.J. McIntyre, R.J. Fluck, and C.W. McIntyre The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease Kidney Int 86 2 2014 407 413
38. C. Agborsangaya, A.T. Toriola, K. Grankvist, and et al. The effects of storage time and sampling season on the stability of serum 25-hydroxy vitamin D and androstenedione Nutr Cancer 62 1 2010 51 57
39. L.D. Bash, B.C. Astor, and J. Coresh Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study Am J Kidney Dis 55 1 2010 31 41
40. C.M. Rebholz, J. Coresh, S.H. Ballew, and et al. Kidney failure and ESRD in the Atherosclerosis Risk in Communities (ARIC) Study: comparing ascertainment of treated and untreated kidney failure in a cohort study Am J Kidney Dis 66 2 2015 231 239